2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Vaccines, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5046 Blinatumomab's outcome on serologic titers and efficacy of revaccination (BOOSTER): A descriptive analysis of humoral immunity in pediatric B-acute lymphoblastic leukemia patients treated with or withoout blinatumomab

Lauren Appell, MD, MS, Kevin Tharappel, MBBS2, Kaylee Johnson3, Andrew Brown, PhD4, Jason Farrar, MD5, Joana Mack, MD6
1 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
5 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
6 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Background: Blinatumomab, a bispecific T-cell engager targeting CD3/CD19, is now part of frontline therapy for most pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). This drug depletes all CD19+ B cells, including memory B cells critical for vaccine-induced humoral immunity, with hypogammaglobulinemia reported in ≥20% of treated patients. For CD19-directed CAR T-cell therapy, which shares the same target and produces analogous B-cell aplasia, international transplant and oncology authorities recommend waiting approximately 6 months after infusion before giving non-live vaccines, on the premise that responses are unreliable until B cells recover. Whether a similar approach to revaccination timing applies after blinatumomab is unknown. Existing infectious disease and oncology guidance for revaccination after childhood leukemia therapy predates the widespread use of B-cell-targeted immunotherapy in frontline pediatric B-ALL and does not address blinatumomab exposure.

 

Methods: This is a retrospective case-control analysis of vaccine-induced immunity in patients aged 1–21 years treated for B-ALL or B-lymphoblastic lymphoma at Arkansas Children's Hospital and Arkansas Children's Northwest. Cases received ≥1 cycle of blinatumomab during frontline therapy; controls did not receive blinatumomab as part of their treatment regimen. Patients with relapsed/refractory disease, prior transplant, or cellular therapy were excluded. Serum titers to tetanus, Haemophilus influenzae type b (Hib), hepatitis B, Streptococcus pneumoniae (23 serotypes), varicella zoster virus, and measles were obtained as part of routine post-therapy immune reconstitution assessment, together with quantitative IgG and peripheral CD19+ and CD20+ B-cell counts. Non-protection was defined by the reporting laboratory's seroprotection threshold for each antigen, and pneumococcal non-protection as lack of protective titers to >70% of the 23 serotypes tested.

 

Results: Of 35 patients, 19 were blinatumomab-exposed cases and 16 were controls. Loss of seroprotection was widespread in both groups and was not greater among blinatumomab recipients. Pneumococcal immunity was uniformly absent: 19 (100%) cases and 16 (100%) controls lacked protective titers to >70% of 23 serotypes. Non-protection in cases vs. controls was 6 (32%) vs. 10 (63%) for hepatitis B, 7 (37%) vs. 6 (38%) for measles, 10 (53%) vs. 10 (63%) for varicella, 2 (11%) vs. 3 (19%) for tetanus, and 6 (32%) vs. 6 (38%) for Hib; for every antigen, the proportion lacking protection was equal to or higher in controls than in blinatumomab-exposed cases. Mean IgG was 654 mg/dL (range 70–1354) in cases vs. 827 mg/dL (392–1430) in controls. Mean peripheral B-cell counts at the time of testing were higher in cases than controls (CD19+ 145 cells/µL, range 0–550, vs. 58, range 8–139; CD20+ 156, range 0–550, vs. 51, range 8–132), indicating that blinatumomab-exposed patients had recovered circulating B cells. No patient in either group retained protection across all antigens.

 

Conclusions: Loss of vaccine-derived humoral immunity after frontline pediatric B-ALL therapy was profound and near-universal in both groups, with complete loss of pneumococcal protection and non-protection reaching 63% for hepatitis B, 63% for varicella, and 38% for measles. Blinatumomab exposure conferred no additional serologic deficit, and B-cell counts had recovered in exposed patients, suggesting the prolonged aplasia seen after CD19 CAR T-cell therapy does not apply. These alarmingly high rates leave a growing survivor population susceptible to vaccine-preventable disease and indicate the critical questions are not blinatumomab-specific: when revaccination should occur, whether B-cell and immunoglobulin recovery should guide that timing, and how durable the resulting seroconversion is. Prospective evaluation is ongoing to address these questions directly.
Kevin Tharappel, MBBS: No relevant conflicts of interest to declare.